Upgrade to SI Premium - Free Trial

Kymera Therapeutics (KYMR)

74.61 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/31/26)

Latest Headlines

Form 4 Kymera Therapeutics, For: Jun 02 Filed by: Jacobs Bruce N. June 3, 2026 7:30 AM - SEC Filing Form 4 Kymera Therapeutics, For: May 26 Filed by: Chadwick Jeremy G May 27, 2026 5:51 PM - SEC Filing Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference May 27, 2026 7:00 AM - Globe NewsWire Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G May 26, 2026 4:42 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G May 26, 2026 4:05 PM - SEC Filing Form 4 Kymera Therapeutics, For: May 19 Filed by: Esposito Pamela May 19, 2026 4:05 PM - SEC Filing Form 4 Kymera Therapeutics, For: May 18 Filed by: Jacobs Bruce N. May 19, 2026 7:30 AM - SEC Filing Form SCHEDULE 13G Kymera Therapeutics, Filed by: T. Rowe Price Investment Management, Inc. May 15, 2026 10:07 AM - SEC Filing Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP May 15, 2026 7:49 AM - SEC Filing Kymera to present KT-621 data at dermatology and lung conferences May 15, 2026 7:00 AM - StreetInsider Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses May 15, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: May 11 Filed by: Ridloff Elena May 11, 2026 4:59 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Ridloff Elena May 11, 2026 4:36 PM - SEC Filing Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: FMR LLC May 6, 2026 11:24 AM - SEC Filing Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 6, 2026 7:00 AM - Globe NewsWire Canaccord Starts Kymera Therapeutics (KYMR) at Buy May 6, 2026 5:09 AM - StreetInsider Kymera presents preclinical IBD data for oral IRF5 degrader KT-579 May 5, 2026 7:01 AM - StreetInsider Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week May 5, 2026 7:00 AM - Globe NewsWire Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent May 5, 2026 6:37 AM - BizWire Kymera Therapeutics (KYMR) PT Lowered to $119 at Morgan Stanley April 30, 2026 12:01 PM - StreetInsider Form 10-Q Kymera Therapeutics, For: Mar 31 April 30, 2026 7:16 AM - SEC Filing Form 8-K Kymera Therapeutics, For: Apr 30 April 30, 2026 7:10 AM - SEC Filing Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c April 30, 2026 7:05 AM - StreetInsider Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update April 30, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: Apr 29 Filed by: Mainolfi Nello April 29, 2026 5:00 PM - SEC Filing Form ARS Kymera Therapeutics, For: Dec 31 April 29, 2026 4:17 PM - SEC Filing Form DEFA14A Kymera Therapeutics, April 29, 2026 4:12 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello April 29, 2026 4:09 PM - SEC Filing Form DEF 14A Kymera Therapeutics, For: Jun 24 April 29, 2026 4:06 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 22 Filed by: Booth Bruce April 24, 2026 4:34 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 22 Filed by: Chadwick Jeremy G April 24, 2026 4:31 PM - SEC Filing Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 April 23, 2026 7:02 AM - Globe NewsWire Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. April 22, 2026 4:52 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. April 22, 2026 4:52 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G April 22, 2026 4:31 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 14 Filed by: Chadwick Jeremy G April 16, 2026 6:30 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 14 Filed by: Goodman Noah April 16, 2026 6:30 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 14 Filed by: Booth Bruce April 16, 2026 6:17 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. April 15, 2026 4:52 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. April 15, 2026 4:51 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G April 15, 2026 4:41 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Booth Bruce April 14, 2026 5:20 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G April 14, 2026 4:38 PM - SEC Filing Kymera receives FDA fast track for asthma drug KT-621 April 13, 2026 7:01 AM - StreetInsider Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma April 13, 2026 7:00 AM - Globe NewsWire Bernstein on US Pharma and Biotech: Who might buy whom? April 13, 2026 5:52 AM - StreetInsider Form 4 Kymera Therapeutics, For: Apr 09 Filed by: Goodman Noah April 10, 2026 4:46 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR) April 10, 2026 6:44 AM - StreetInsider Form 144 Kymera Therapeutics, Filed by: Goodman Noah April 9, 2026 4:28 PM - SEC Filing Gilead exercises option for Kymera's cancer drug candidate KT-200 April 9, 2026 7:03 AM - StreetInsider Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate April 9, 2026 7:01 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: Mar 31 Filed by: Ridloff Elena April 1, 2026 7:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Mar 31 Filed by: Chadwick Jeremy G April 1, 2026 7:00 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Ridloff Elena April 1, 2026 4:42 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G April 1, 2026 4:42 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G March 31, 2026 4:22 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Ridloff Elena March 31, 2026 4:20 PM - SEC Filing Kymera presents atopic dermatitis trial data at dermatology meeting March 30, 2026 4:21 AM - StreetInsider Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting March 28, 2026 11:00 AM - Globe NewsWire Form 8-K Kymera Therapeutics, For: Mar 25 March 27, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: VANGUARD GROUP INC March 27, 2026 10:18 AM - SEC Filing Form 4 Kymera Therapeutics, For: Mar 23 Filed by: Chadwick Jeremy G March 25, 2026 5:15 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G March 23, 2026 4:37 PM - SEC Filing Form 4 Kymera Therapeutics, For: Mar 20 Filed by: Esposito Pamela March 20, 2026 6:30 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Esposito Pamela March 20, 2026 4:35 PM - SEC Filing RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns' March 18, 2026 9:21 AM - StreetInsider Form 4 Kymera Therapeutics, For: Mar 11 Filed by: Chadwick Jeremy G March 11, 2026 6:51 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G March 11, 2026 4:40 PM - SEC Filing Kymera to present KT-621 atopic dermatitis trial data at dermatology meeting March 10, 2026 7:01 AM - StreetInsider Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting March 10, 2026 7:01 AM - Globe NewsWire Full Article List